TARO-DEFERIPRONE 1000 MG
DEFERIPRONE : 1000 MG · DIN 02553112 · TARO PHARMACEUTICALS INC
Health Canada status: MARKETED
What is TARO-DEFERIPRONE?
TARO-DEFERIPRONE 1000 MG contains DEFERIPRONE : 1000 MG. It is listed in the Health Canada Drug Product Database under DIN 02553112, held by TARO PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 03-Mar-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARO-DEFERIPRONE used for?
Taro - Deferiprone (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate, and for the treatment of patients with transfusional iron overload due to sickle cell disease or other anemias.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02553112 |
|---|---|
| Brand name | TARO-DEFERIPRONE |
| Generic / active ingredient | DEFERIPRONE : 1000 MG |
| Manufacturer | TARO PHARMACEUTICALS INC |
| Strength | 1000 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | V03AC02 DEFERIPRONE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 03-Mar-2025 |
How is it stored and handled?
null
How is it supplied?
Bottles of 50 tablets
What can be used instead?
Other Canadian products sharing ATC code V03AC02 DEFERIPRONE. 5 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| FERRIPROX | 100 MG | SOLUTION | CHIESI CANADA CORP. | MARKETED | DIN 02436523 |
| FERRIPROX | 1000 MG | TABLET | CHIESI CANADA CORP. | MARKETED | DIN 02436558 |
| FERRIPROX | 500 MG | TABLET | CHIESI CANADA CORP. | MARKETED | DIN 02436531 |
| FERRIPROX MR | 1000 MG | TABLET (EXTENDED-RELEASE) | CHIESI CANADA CORP. | MARKETED | DIN 02536579 |
Who else supplies DEFERIPRONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DEFERIPRONE appears in 37 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.